Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Haematologica - 1 Jul 2016

Kosmider Olivier, Passet Marie, Santini Valeria, Platzbecker Uwe, Andrieu Valérie, Zini Gina, Beyne-Rauzy Odile, Guerci Agnès, Masala Erico, Balleari Enrico, Bulycheva Ekaterina, Dreyfus François, Fenaux Pierre, Fontenay Michaela, Park Sophie

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Mutation
Share to Myelodysplastic Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Risk Factors

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 27056923
DOI: 10.3324/haematol.2016.142695
PMCID: PMC5004472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?PMID 27056923Read ↗

Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic DiversitySemantic proximity Read ↗

The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders.Semantic proximity Read ↗

Germline variants drive myelodysplastic syndrome in young adultsSemantic proximity Read ↗

MUTATIONAL PROFILE ENABLES THE IDENTIFICATION OF A HIGH RISK SUBGROUP IN MYELODYSPLASTIC SYNDROMES WITH ISOLATED TRISOMY 8Semantic proximity Read ↗

From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromesSemantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

Genetic abnormalities in myelodysplastic syndrome.Semantic proximity Read ↗

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.Semantic proximity Read ↗

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.Semantic proximity Read ↗

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.Semantic proximity Read ↗

Genetic mutations in patients with acute myeloid leukemia and leukostasis.Semantic proximity Read ↗

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.